1,2-distearoylphosphatidylethanolamine has been researched along with Adenocarcinoma, Basal Cell in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Evjen, TJ; Fossheim, SL; Hagtvet, E; Nilssen, EA; Olsen, DR | 1 |
Benazzouz, F; Cordobes, MD; de Beco, V; Moretti, JL; Starzec, A | 1 |
2 other study(ies) available for 1,2-distearoylphosphatidylethanolamine and Adenocarcinoma, Basal Cell
Article | Year |
---|---|
Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Doxorubicin; Drug Carriers; Liposomes; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phonophoresis; Phosphatidylethanolamines; Prostatic Neoplasms; Tissue Distribution; Xenograft Model Antitumor Assays | 2011 |
Uptake of liposome-encapsulated 99Tcm-MIBI by sensitive and multidrug-resistant tumour cell lines.
Topics: Adenocarcinoma; Biological Transport; Breast Neoplasms; Carcinoma, Small Cell; Cholesterol; Drug Resistance, Multiple; Female; Humans; Kinetics; Liposomes; Lung Neoplasms; Mouth Neoplasms; Phosphatidylcholines; Phosphatidylethanolamines; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Tumor Cells, Cultured | 1999 |